|
**Overview**: **Anemia Panel 2 Profile****Introduction**: The Anemia Panel 2 Profile is a diagnostic tool designed to conduct advanced anemia screening using serum and whole blood samples. Associated with conditions like hemolytic anemia and aplastic anemia, these disorders present with fatigue, pallor, and severe complications if untreated, particularly in individuals with complex anemia conditions. Per the 2023 Hematology guidelines, the test employs biochemistry and hematology with immunoassay and automated cell counter technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for anemia screening in clinical settings. This diagnostic falls under anemia screening and targets individuals with suspected advanced anemia, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.**Other Names**: Anemia 2 Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry and hematology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by hematology labs, this test advanced advanced anemia diagnostics.**Purpose**: The test screens for 30 parameters including hemoglobin to guide anemia assessment, assess inflammatory and nutritional status, and inform treatment and prevention strategies.**Test Parameters**: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. Differential Count, 6. ESR, 7. Iron, 8. TIBC, 9. Ferritin, 10. Transferrin Saturation, 11. Vitamin B12, 12. Folate, 13. Reticulocyte Count, 14. Hematocrit, 15. MCV, 16. MCH, 17. MCHC, 18. RDW, 19. CRP, 20. Soluble Transferrin Receptor, 21. Total Protein, 22. Albumin, 23. Globulin, 24. Erythropoietin, 25. Haptoglobin, 26. Serum Folate, 27. Peripheral Smear, 28. Iron Binding Capacity, 29. Transferrin, 30. Hepcidin.**Pretest Condition**: Fasting 10-12 hours required; patients should report fatigue, pallor, or recent health changes.**Specimen**: 3 mL serum in 1 SST, 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours (Serum), 48 hours (Blood) with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days (Serum, Blood) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months (Serum) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fatigue, pallor, prior anemia reactions, or family history of blood disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated anemia including organ damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and automated cell counter and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent transfusions can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible advanced anemia, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early disease stages.**Specialist Consultation**: General practitioners or specialists in hematology or internal medicine should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Iron studies, bone marrow biopsy, or genetic testing for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute inflammation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Hematology Guidelines 2023, Journal of Blood Medicine 2024, Biochemistry 2025. |
